Lunit6th floor, 175 Yeoksam-ro, Gangnam-gu, Seoul, South KoreaeMail:Website:https://lunit.ioLatest from LunitGene expressionLunit adds AstraZeneca for NSCLC biomarker screening AIBy LabPulse.com staff writersCompanies to integrate Scope Genotype Predictor into pathology workflows to screen for actionable mutations in non-small cell lung cancer research.November 18, 2024Non Small Cell Lung CancerLunit to present results of AI-based immunotherapy predictive test study at WCLC 2023By LabPulse.com staff writersLunit announced the presentation of data from a collaborative study on the use of the Lunit SCOPE IO test to predict immunotherapy treatment outcomes in lung cancer at the 2023 World Conference on Lung Cancer (WCLC 2023).August 28, 2023CancerLunit, Japan national cancer center collaborate on AI-based pathology for oncologyBy LabPulse.com staff writersIn collaborative studies with the national cancer center, researchers are evaluating the potential of the Lunit Scope artificial intelligence biomarker platform to predict clinical outcomes for rectal cancer.May 30, 2023Financial ResultsGuardant Health shares rise on Q4 growth in clinical, biopharma testingBy Leo O'ConnorFor Q4, the firm reported 36,000 tests to clinical customers and 8,200 tests to biopharmaceutical customers, representing an increase of 41% and 24%, respectively, over the fourth quarter of 2021.February 24, 2023Artificial IntelligenceGuardant NSCLC biomarker test to incorporate Lunit’s AI-based scoring algorithmBy LabPulse.com staff writersThe integrated Lunit Scope PD-L1 algorithm will augment the TissueNext test’s detection of the PD-L1 biomarker in tissue samples using an AI-based scoring system.February 1, 2023Artificial IntelligenceLunit promotes studies to be presented at 2022 ASCO meetingBy LabPulse.com staff writersSeven poster presentations and four online publications, including research on AI biomarkers, have been accepted by ASCO, with findings demonstrating the practical use of Lunit's AI software in the pathological assessment of cancer, the company said.April 28, 2022Artificial IntelligenceLunit promotes AI study to guide therapy of NSCLC patientsBy LabPulse.com staff writersThe Lunit Scope IO is an AI-powered whole-slide image (WSI) analyzer of tumor-infiltrating lymphocytes (TIL) in the tumor microenvironment. The software is designed to define three immune phenotypes (IPs): inflamed, immune-excluded, and immune-desert.March 17, 2022Pathology, histologyLunit receives $26M funding from Guardant HealthBy LabPulse.com staff writersLunit has developed Lunit Scope, a software application to perform tissue analysis of pathology images stained with hematoxylin and eosin. Lunit researchers recently presented results at the American Society of Clinical Oncology 2021 annual meeting showing that Lunit Scope was able to identify 50% more patients who would respond to immunotherapy compared with traditional diagnostic pathology.July 18, 2021Pathology, histologyLunit presents findings on Lunit Scope pathology AI at ASCOBy LabPulse.com staff writersThe presentations feature the company's Lunit Scope, an AI software application that analyzes tissue slide images. One finding showed that Lunit Scope IO can be used as a biomarker for the treatment of multiple cancer types. The software analyzes tumor-infiltrating lymphocytes in tissue slides for cancer patients, assigning a score to each criterion.June 3, 2021
